OTR Global downgraded its view of Exact Sciences (EXAS) to Mixed from Positive, citing checks that found Q4 Cologuard prescriptions met most sources’ expectations, but that the 2025 growth outlook is viewed as “modest.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXAS:
- Netflix upgraded, Electronic Arts downgraded: Wall Street’s top analyst calls
- Exact Sciences initiated with an Overweight at Barclays
- Exact Sciences validates Oncodetect ability to detect molecular residual Disease
- Exact Sciences Boosts Finances and Plans New Launches
- Exact Sciences reports preliminary Q4 revenue $713M, consensus $694.76M